|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG007698674 |
003 |
DE-627 |
005 |
20230605131153.0 |
007 |
cr uuu---uuuuu |
008 |
210616s2023 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG007698674
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)TCTR20210506001
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)Nil Known
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a An open-label randomized controlled trial to evaluate the efficacy of antihistamine premedication and infusion prolongation in prevention of hypersensitivity reaction to oxaliplatin.
|b An open-label randomized controlled trial to evaluate the efficacy of antihistamine premedication and infusion prolongation in prevention of hypersensitivity reaction to oxaliplatin.
|
264 |
|
1 |
|c 2023
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 06-05-2021, Last updated: 2023-06-05
|
650 |
|
4 |
|a Medical Condition: Hypersensitivity reaction (HSR) is a common toxicity associated with oxaliplatin. Oxaliplatin is a chemotherapy mainly used in gastrointestinal malignancies especially colorectal cancer. The incidences of oxaliplatin induced HSR vary from 12% to 25% (1-5) (6-8) (9, 10). Although it is usually mild to moderate severity (11), it could be severe (9, 10) and result in treatment discontinuation. Oxaliplatin induced HSR is a type I hypersensitivity. It usually occurs in later cycles of treatment course. In a common oxaliplatin based regimen, FOLFOX, it is more likely to firstly occur in seventh to ninth cycle of twelve-cycle treatment course.(12). Although many studies identified risk factors for HSRs, the most consistent risk factor is the number of oxaliplatin administered. (13-15) To date, there have been a few studies exploring preventive strategies for oxaliplatin induced HSRs. Most of them were retrospective or single-arm prospective studies. In this study, we conducted a randomization controlled trial to explore the efficacy of additional antihistamine premedication and infusion prolongation in prevention of oxaliplatin induced HSRs. Oxaliplatin/ Hypersensitivity reaction (HSR)/ Prevention;Oxaliplatin/ Hypersensitivity reaction (HSR)/ Prevention
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 2
|
650 |
|
4 |
|a Recruitment Status: Completed
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 29. Mai
|
773 |
1 |
8 |
|g year:2023
|g day:29
|g month:05
|
856 |
4 |
0 |
|u https://www.thaiclinicaltrials.org/show/TCTR20210506001
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2023
|b 29
|c 05
|